VRCA Logo

Verrica Pharmaceuticals Inc. (VRCA) 

NASDAQ
Market Cap
$32.01M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
30 of 776
Rank in Industry
26 of 433

Largest Insider Buys in Sector

VRCA Stock Price History Chart

VRCA Stock Performance

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration …

Insider Activity of Verrica Pharmaceuticals Inc.

Over the last 12 months, insiders at Verrica Pharmaceuticals Inc. have bought $12.5M and sold $1.48M worth of Verrica Pharmaceuticals Inc. stock.

On average, over the past 5 years, insiders at Verrica Pharmaceuticals Inc. have bought $8.07M and sold $1.11M worth of stock each year.

Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (10 percent owner) — $187.55M.

The last purchase of 115,774 shares for transaction amount of $838,204 was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2023‑12‑29.

List of Insider Buy and Sell Transactions, Verrica Pharmaceuticals Inc.

2024-08-27SalePRESIDENT AND CEO
9,021
0.0211%
$2.46$22,192-34.96%
2024-08-27SaleCHIEF LEGAL OFFICER
9,530
0.0223%
$2.46$23,444-34.96%
2024-08-27SaleChief Medical Officer
3,601
0.0084%
$2.46$8,858-34.96%
2024-08-27SaleCHIEF COMMERCIAL OFFICER
8,993
0.0211%
$2.46$22,123-34.96%
2024-08-27SaleCHIEF FINANCIAL OFFICER
7,899
0.0185%
$2.46$19,432-34.96%
2024-08-26SalePRESIDENT AND CEO
24,979
0.0606%
$2.66$66,444-36.19%
2024-08-26SaleCHIEF LEGAL OFFICER
26,183
0.0635%
$2.66$69,647-36.19%
2024-08-26SaleChief Medical Officer
9,888
0.024%
$2.66$26,302-36.19%
2024-08-26SaleCHIEF COMMERCIAL OFFICER
24,709
0.0599%
$2.66$65,726-36.19%
2024-08-26SaleCHIEF FINANCIAL OFFICER
21,820
0.0529%
$2.66$58,041-36.19%
2024-07-23SalePRESIDENT AND CEO
154
0.0003%
$6.98$1,075+1.86%
2024-07-23SaleCHIEF LEGAL OFFICER
91
0.0002%
$6.98$635+1.86%
2024-07-23SaleChief Medical Officer
86
0.0002%
$6.98$600+1.86%
2024-07-23SaleCHIEF COMMERCIAL OFFICER
115
0.0003%
$6.98$803+1.86%
2024-07-22SalePRESIDENT AND CEO
32,469
0.0765%
$7.06$229,231-72.95%
2024-07-22SaleCHIEF LEGAL OFFICER
21,649
0.051%
$7.06$152,842-72.95%
2024-07-22SaleChief Medical Officer
18,421
0.0434%
$7.06$130,052-72.95%
2024-07-22SaleCHIEF COMMERCIAL OFFICER
25,461
0.06%
$7.06$179,755-72.95%
2023-12-29Purchase10 percent owner
115,774
0.2752%
$7.24$838,204-21.10%
2023-12-28Purchase10 percent owner
126,116
0.2934%
$7.08$892,901-21.92%

Insider Historical Profitability

13.24%
PERCEPTIVE ADVISORS LLC10 percent owner
7099182
16.638%
$0.75100<0.0001%
White TedPRESIDENT AND CEO
215967
0.5061%
$0.7577+0.47%
Hayes Christopher G.CHIEF LEGAL OFFICER
105773
0.2479%
$0.7537+53.25%
Goldenberg GaryChief Medical Officer
94261
0.2209%
$0.7517+61.6%
Bonaccorso JoeCHIEF COMMERCIAL OFFICER
73114
0.1714%
$0.7517<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Perceptive Advisors$42.03M16.747.1M0%+$00.03
Avoro Capital Advisors Llc$23.68M9.434M0%+$00.28
Fidelity Investments$8.93M3.561.51M+0.01%+$1,101.12<0.01
The Vanguard Group$7.51M2.991.27M+0.6%+$45,045.28<0.0001
BlackRock$6.6M2.631.11M-1.91%-$128,363.38<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.